Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Phase 1

Completed

Conditions: Bladder Urothelial Carcinoma
Stage III Bladder Cancer AJCC v6 and v7
Stage I Bladder Cancer AJCC v6 and v7
Stage II Bladder Cancer AJCC v6 and v7

Interventions: Drug: Paclitaxel
Radiation: Radiation Therapy
Biological: Trastuzumab

First Posted Date: 2005-10-13

Last Posted Date: 2022-07-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT00238420

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Mobile Infirmary Medical Center, Mobile, Alabama, United States
🇺🇸
Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States

and more 180 locations

Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Phase 2

Completed

Conditions: Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer

Interventions: Drug: cediranib maleate
Other: laboratory biomarker analysis

First Posted Date: 2005-10-13

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 44

Registration Number: NCT00238394

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Phase 2

Completed

Conditions: Adenocarcinoma of the Extrahepatic Bile Duct
Adenocarcinoma of the Gallbladder
Adenocarcinoma With Squamous Metaplasia of the Gallbladder
Cholangiocarcinoma of the Extrahepatic Bile Duct
Cholangiocarcinoma of the Gallbladder
Recurrent Extrahepatic Bile Duct Cancer
Recurrent Gallbladder Cancer
Squamous Cell Carcinoma of the Gallbladder
Unresectable Extrahepatic Bile Duct Cancer
Unresectable Gallbladder Cancer

Interventions: Drug: sorafenib tosylate
Other: laboratory biomarker analysis

First Posted Date: 2005-10-13

Last Posted Date: 2013-01-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00238212

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

Phase 2

Completed

Conditions: Stage III Uterine Sarcoma
Uterine Carcinosarcoma
Stage IV Uterine Sarcoma
Recurrent Uterine Sarcoma

Interventions: Drug: sorafenib tosylate

First Posted Date: 2005-10-13

Last Posted Date: 2015-11-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 56

Registration Number: NCT00238121

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Central Illinois Hematology Oncology Center, Springfield, Illinois, United States
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

and more 4 locations

Use of Midlevel Providers in Diabetes Management

Not Applicable

Completed

Conditions: Diabetes Mellitus

First Posted Date: 2005-10-12

Last Posted Date: 2010-01-15

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 600

Registration Number: NCT00237094

Locations: 🇺🇸
Deaconess Billings Clinic Center on Aging, Billings, Montana, United States

Infectious Agents in Pediatric Crohn's

Completed

Conditions: Crohn's Disease
Inflammatory Bowel Disease

First Posted Date: 2005-10-12

Last Posted Date: 2010-03-18

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 500

Registration Number: NCT00237055

Locations: 🇺🇸
Emory University School of Medicine; Emory Children's Center, Atlanta, Georgia, United States

Genetics of Interstitial Cystitis

Completed

Conditions: Interstitial Cystitis
Painful Bladder Syndrome

First Posted Date: 2005-10-12

Last Posted Date: 2020-03-17

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registration Number: NCT00237081

Locations: 🇺🇸
University of Maryland Interstitial Cystitis Center, Baltimore, Maryland, United States

Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus

Phase 1

Completed

Conditions: Barrett Esophagus

Interventions: Drug: defined green tea catechin extract
Other: placebo

First Posted Date: 2005-10-06

Last Posted Date: 2014-09-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT00233935

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Effect of Omega-3 PUFA Supplementation in NAFLD Patients

Phase 2

Completed

Conditions: Non-Alcoholic Fatty Liver Disease

Interventions: Dietary Supplement: Omega-3 fatty acid diet supplementation
Dietary Supplement: safflower oil

First Posted Date: 2005-09-30

Last Posted Date: 2013-07-10

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 30

Registration Number: NCT00230113

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

Iron Depletion Therapy for Type 2 DM and NAFLD

Phase 2

Completed

Conditions: Non-Alcoholic Fatty Liver Disease
Diabetes Mellitus

First Posted Date: 2005-09-30

Last Posted Date: 2012-11-07

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 15

Registration Number: NCT00230087

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy